Lesaffre and Recombia Biosciences Announces Strategic Partnership to Advance Innovative Gene Editing Technology

Recombia Biosciences announces the launch of operations in Brisbane, California. The company aims to harness its proprietary genome editing technologies to accelerate the development of yeast for sustainable production of fermented ingredients. For the next few years Recombia and Lesaffre will be joining forces in the area of yeast strain development. With its partnership with Recombia, Lesaffre is investing in major pioneering technology. The ability to generate thousands of yeast strains in parallel, combined with laboratory automation, is expected to exponentially accelerate development of projects in the areas of health, the environment, and energy. The partnership also signifies Lesaffre's entry into the world of Synthetic Biology, considered to be the major biotechnological opportunity of this decade. Recombia Biosciences was founded by three Stanford University researchers in 2019 as a spin-off from the prestigious Stanford Genome Technology Center (SGTC). Recombia's technologies are based upon techniques that increase the efficiency of genome editing and enable engineering of yeast at very high throughput. The strategic collaboration with Lesaffre aims to advance Recombia's proprietary gene editing technologies to identify new yeast strains, discover novel yeast physiology of industrial relevance and optimize the production of biosourced ingredients and biofuels.